308.78
price up icon0.26%   0.79
after-market アフターアワーズ: 308.78
loading
前日終値:
$307.99
開ける:
$306.45
24時間の取引高:
532.05K
Relative Volume:
0.52
時価総額:
$39.64B
収益:
$2.35B
当期純損益:
$-269.70M
株価収益率:
-147.74
EPS:
-2.09
ネットキャッシュフロー:
$-75.39M
1週間 パフォーマンス:
+1.57%
1か月 パフォーマンス:
+8.23%
6か月 パフォーマンス:
+26.55%
1年 パフォーマンス:
+92.52%
1日の値動き範囲:
Value
$302.32
$309.63
1週間の範囲:
Value
$295.82
$309.63
52週間の値動き範囲:
Value
$152.30
$310.22

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
名前
Alnylam Pharmaceuticals Inc
Name
セクター
Healthcare (1174)
Name
電話
(617) 551-8200
Name
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
職員
2,230
Name
Twitter
@alnylam
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
ALNY's Discussions on Twitter

ALNY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.78 39.64B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.91 114.57B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.68 55.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.64B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
264.42 28.55B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-31 開始されました Redburn Atlantic Buy
2025-03-24 アップグレード JP Morgan Neutral → Overweight
2024-11-12 ダウングレード Wolfe Research Peer Perform → Underperform
2024-10-16 開始されました Scotiabank Sector Outperform
2024-08-16 アップグレード Goldman Neutral → Buy
2024-02-16 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-12-08 開始されました Wells Fargo Equal Weight
2023-10-11 ダウングレード Oppenheimer Outperform → Perform
2023-09-29 開始されました Raymond James Outperform
2023-05-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-26 開始されました SMBC Nikko Neutral
2023-03-21 開始されました Bernstein Outperform
2023-01-18 開始されました Canaccord Genuity Buy
2022-09-09 再開されました Morgan Stanley Equal-Weight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-06-27 ダウングレード Guggenheim Buy → Neutral
2022-06-07 開始されました William Blair Outperform
2022-04-25 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-03-01 開始されました Citigroup Buy
2022-02-03 アップグレード Guggenheim Neutral → Buy
2022-01-03 アップグレード Piper Sandler Neutral → Overweight
2021-11-22 アップグレード Goldman Neutral → Buy
2021-11-22 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-01 アップグレード Oppenheimer Perform → Outperform
2021-10-04 アップグレード UBS Neutral → Buy
2021-08-04 ダウングレード Piper Sandler Overweight → Neutral
2021-02-22 ダウングレード Guggenheim Buy → Neutral
2021-02-12 ダウングレード Citigroup Buy → Neutral
2021-02-12 繰り返されました H.C. Wainwright Buy
2021-01-25 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-09-30 再開されました Berenberg Hold
2020-09-08 開始されました Citigroup Buy
2020-08-11 ダウングレード Oppenheimer Outperform → Perform
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2020-05-07 ダウングレード JP Morgan Overweight → Neutral
2020-04-24 再開されました Evercore ISI Outperform
2020-03-19 開始されました Berenberg Buy
2019-12-19 繰り返されました Chardan Capital Markets Buy
2019-11-20 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-05-23 再開されました Goldman Neutral
2019-04-12 開始されました Evercore ISI Outperform
2019-03-06 アップグレード Evercore ISI In-line → Outperform
2019-03-05 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-01-23 開始されました UBS Neutral
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-13 繰り返されました Stifel Buy
2018-08-07 アップグレード Stifel Hold → Buy
2018-05-04 繰り返されました Stifel Hold
2018-03-28 開始されました Evercore ISI In-line
すべてを表示

Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース

pulisher
Jun 16, 2025

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Antisense Oligonucleotides Market is expected to reach US$ - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st

Jun 16, 2025
pulisher
Jun 14, 2025

Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada

Jun 14, 2025
pulisher
Jun 13, 2025

Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 12, 2025

Where are the Opportunities in (ALNY) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals

Jun 12, 2025
pulisher
Jun 12, 2025

ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance

Jun 10, 2025
pulisher
Jun 09, 2025

Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra

Jun 09, 2025
pulisher
Jun 09, 2025

Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire

Jun 09, 2025
pulisher
Jun 09, 2025

siRNA on the Precipice as Candidates Reach Beyond the Liver - BioSpace

Jun 09, 2025
pulisher
Jun 07, 2025

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - mx.advfn.com

Jun 07, 2025
pulisher
Jun 07, 2025

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 06, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech

Jun 06, 2025
pulisher
Jun 05, 2025

Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review

Jun 05, 2025
pulisher
Jun 05, 2025

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga

Jun 05, 2025
pulisher
Jun 04, 2025

Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News

Jun 04, 2025
pulisher
Jun 04, 2025

Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O

Jun 04, 2025
pulisher
Jun 04, 2025

CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com

Jun 04, 2025
pulisher
Jun 04, 2025

US appeals court sides with Moderna on COVID patent claims - Reuters

Jun 04, 2025
pulisher
Jun 03, 2025

Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.

Jun 03, 2025
pulisher
Jun 03, 2025

Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright - Insider Monkey

Jun 03, 2025
pulisher
May 31, 2025

(ALNY) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Alnylam stock soars to all-time high of $304.52 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Alnylam stock soars to all-time high of $304.52 - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

JPMorgan lifts Alnylam stock price target to $330 By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace

May 28, 2025
pulisher
May 28, 2025

RNAi Leader Alnylam Set for Major Presentation at Goldman Sachs Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan

May 28, 2025

Alnylam Pharmaceuticals Inc (ALNY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$551.22
price down icon 4.62%
biotechnology ONC
$264.42
price down icon 1.93%
$106.33
price down icon 0.23%
$522.68
price down icon 1.24%
$19.95
price up icon 0.86%
大文字化:     |  ボリューム (24 時間):